Cooperative Treatment of Breast Cancer Using an Irinotecan/IR‐820 Co‐loaded Hollow Mesoporous Silica Nanoparticles Nanoplatform

Abstract

BackgroundNanomaterial‐based multimodal systems are promising candidates for exerting synergistic therapeutic effects in cancer therapy.1 Combination therapy through different mechanisms can cooperatively inhibit cancer progression and overcome the limitations of monotherapies.2 In this study, we used hollow mesoporous silica nanoparticles (HMSNs) as a biocompatible carrier to co‐load chemotherapy drugs Irinotecan and near‐infrared (NIR) IR‐820 dye, which enhanced anti‐tumor efficacy by combining chemotherapy and phototherapy.MethodsHollow mesoporous silica nanoparticles (HMSNs) were prepared by an established method 1, then IR 820 and Irinotecan were loaded into the HMSNs by electrostatic attracting method. The successful synthesis of HMSNs/Irinotecan/IR820 (HMII) nanocomplex were confirmed by Fourier Transform Infrared (FTIR) spectroscopy and Fluorescence spectra. Confocal laser scanning microscopy (CLSM) was used to detect the cellular uptake of HMII. The photothermal conversion efficiency and anti‐tumor efficiency in mouse mammary cells (EMT‐6) bearing mice were further evaluated.ResultsThe mean diameter of HMII were around 80 nm, which possessed the advantages of homogenous particle size, high stability, and good safety. The results demonstrated that HMII enhanced the delivery of Irinotecan and IR‐820 into EMT‐6 cells. HMII generated a high temperature upon a NIR laser irradiation (808 nm), and showed higher therapeutic efficacy in EMT‐6‐bearing mice compared to either HMII without laser or free drug with a laserConclusionBy combining chemotherapy and phototherapy (PTT), HMII efficiently inhibited the growth of breast cancer in mice. This nanosystem provides promising applicability for combination therapy of breast cancer.Support or Funding InformationWe would like to thank the National Natural Science Foundation of China (81671821, 81471785, 31470959, 31470906, and 11502049)This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.